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We read with interest the article by O'Byrne et al. about the presentation of 2 and review of 35 patients with MTO1-deficiency [1]. We have the
following comments and concerns.
Patient-1 had febrile seizures since age 2.5y and absence seizures since age 3.5y [1]. Which antiepileptic drugs (AEDs) were administered during
the course? This issue is crucial since some AEDs, such as valproic acid, carbamazepine, phenytoin, or phenobarbital may exhibit mitochondrion-
toxic effects, and may worsen the phenotype [2]. Particularly valproic acid may exhibit severe side effects in patients with a mitochondrial disorder
(MID) and may even cause death, particularly in patients carrying POLG1 mutations [3]. Seizures were refractory to treatment at age 11y [1]. Was
refractoriness attributable to the mitochondrion-toxic effect of the applied AEDs?
At age 11y patient-1 developed multiple, transient T2-hyperintensities within the peduncles, basal ganglia, and the cortex [1]. Were these
imaging abnormalities stroke-like lesions, the morphological equivalent of stroke-like episodes (SLEs)? Did the phenotype deteriorate during this
episode? Were these lesions hyperintense on DWI and ADC, thus indicative of a vasogenic edema, typical for a stroke-like lesion? Did the patient
receive L-arginine during this episode, which is frequently recommended as acute treatment of SLEs [4]. Were other causes of the transient T2-
hyperintensities, such as ADEM or an epiphenomenon of the seizure activity, considered?
One of the dominant phenotypic features seems to be hypertrophic cardiomyopathy and arrhythmias (Table 1) [1]. How many of the analysed
patients developed heart failure or systolic dysfunction and required cardiac therapy? Was non-compaction, frequently associated with MIDs [5],
detected in any patient?
Overall, this interesting study could be more meaningful by providing more details about the AED treatment and its influence on the phenotype,
about the cerebral imaging findings, about the cardiac involvement in the disease, and about the family history.
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Table 1
Phenotypic features in 35 patients carrying MTO1 mutations.
Feature Number of patients
Brain
Intellectual disability 26
Muscle hypotonia 22
Failure to thrive 15
Abnormal cerebral imaging 15
Seizures 12
Optic atrophy 9
Ataxia 7
Developmental delay 6
Dystonia 1
Eyes
Cataract 1
Pigmentary retinopathy 1
Heart
Hypertrophic cardiomyopathy 27
Cardiac arrhythmias 8
Dilated cardiomyopathy 1
Muscle
Lactic acidosis 20
Myopathy 7
Respiratory insufficiency 5
Endocrine abnormalities
Hypoglycemia 2
Short stature 1
Gastrointestinal
Feeding difficulties 15
Hepatopathy 3
Renal
Hypocalcemia 1
Tubulopathy 1
Others
Dysmorphism 1
Microcephaly 1
Hyper-ammonemia 1
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